Listed by the USPTO as METCALF, MATTHEW CURRAN
Tech Center 1600 • Art Units: 1622 1632 1647 1674
This examiner grants 38% of resolved cases
METCALF, MATTHEW CURRAN examines in tech center 1600 and art unit 1622. The profile contains 8 resolved cases and a 37.5% allowance rate. The interview lift is 71.4%, indicating a strong positive association in the available record. The median time to allowance is 1300 days.
The listed companies are University of Florida Research Foundation Inc., Novartis AG, and Bristol-Myers Squibb Company. The listed firms are FISH & RICHARDSON P.C. (TC), BakerHostetler, and Biospark Intellectual Property Law. Because the resolved-case record is limited, the figures should be treated as an early indicator rather than a stable long-term pattern. The relationship between the allowance rate and interview lift supports investing in interview preparation, while the median timing calls for careful management of prosecution expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18691666 | CELLULAR THERAPY TO SUPPRESS IMMUNE RESPONSE | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
| 18294609 | CELL CULTURE METHODS FOR PRODUCING THERAPEUTIC PROTEINS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18562108 | METHODS FOR THE TREATMENT OF OSTEOARTHRITIS | Non-Final OA | Novartis AG |
| 18289049 | ASSESSING AND TREATING CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18685350 | COMPOSITIONS AND METHODS COMPRISING LIPID ASSOCIATED TRANSMEMBRANE DOMAINS | Non-Final OA | The Regents of the University of California |
| 18589384 | MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18518384 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | Non-Final OA | Juno Therapeutics, Inc. |
| 18296711 | IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES | Non-Final OA | SANOFI |
| 18292247 | COMPOSITIONS AND METHODS FOR ENHANCING CAR T CELL EFFICACY THROUGH THE ENGINEERED SECRETION OF C. PERFRINGENS NEURAMINIDASE | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18292574 | CAR-EXPRESSING IMMUNE CELLS THAT SPECIFICALLY TARGET MESOTHELIN AND USES THEREOF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18281372 | NON-ACTIVATING ANTIBODY VARIANTS | Final Rejection | GENMAB A/S |
| 18261158 | NOVEL ALLERGEN ISOFORM VARIANTS | Final Rejection | PHADIA AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy37.5% of resolved applications examined by Matthew Curran Metcalf were allowed (8 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.
This examiner's interview lift is +71.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Matthew Curran Metcalf took 1,300 days on average from filing to allowance.
Matthew Curran Metcalf examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
